A Chinese herbal formula for persistent high-risk HPV after treatment
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This trial tests a Chinese herbal formula (Cnidium Monnieri Detoxification Formula) to see if it can clear high-risk HPV that remains in the cervix even after surgery or other treatments. It is for people who have completed treatment for cervical or vaginal precancer or cancer but still test positive for high-risk HPV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 25 and 75 years old and have had sexual activity.
- You have tested positive for high-risk HPV for at least 6 months after finishing treatment for cervical or vaginal precancer or cancer.
- You have not received any other local or whole-body treatment for HPV in the last 3 months.
- You are not pregnant or breastfeeding.
- You have no other uncontrolled cancers or serious heart, lung, liver, kidney, or blood clotting problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial tests whether a combination of Chinese medicine and a probiotic (Lactobacillus) can help clear a long-lasting HPV infection. It's for women who have had the same high-risk HPV type for over a year and have not developed serious cervical changes.
This study tests a new treatment called NWRD09 for women with a long-lasting HPV16 infection that shows concerning cell changes in the cervix. The goal is to see if this treatment can help your immune system clear the infection and prevent it from developing into cervical cancer.
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
This study uses a detailed DNA test to look for high-risk HPV in people with long-lasting (chronic) infection after treatment or with return of abnormal cells. It may help improve how clinicians monitor high-risk HPV and decide next steps.
This trial tests an antibacterial liquid (Paiteling®) to see if it can clear a persistent high-risk HPV infection of the cervix. It may be an option for women whose HPV has lasted 2 years or more and whose cervical biopsy shows only mild changes.
Hear when a new Human Papillomavirus (HPV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.